Brief: Verrica Pharmaceuticals’ Partner Torii Pharmaceutical Announces Positive Top-Line Results From Confirmatory Phase 3 Trial Of TO-208

Verrica Pharmaceuticals

15/12/2023 11:24

Dec 15 (Reuters) - Verrica Pharmaceuticals Inc  VRCA.O :
    * VERRICA PHARMACEUTICALS’ DEVELOPMENT AND COMMERCIALIZATION
PARTNER, TORII PHARMACEUTICAL CO., LTD., ANNOUNCES POSITIVE
TOP-LINE RESULTS FROM A CONFIRMATORY PHASE 3 TRIAL OF TO-208 FOR
THE TREATMENT OF MOLLUSCUM CONTAGIOSUM IN JAPAN
    * VERRICA PHARMACEUTICALS INC - TO-208 WAS WELL TOLERATED
DURING
STUDY
    * VERRICA PHARMACEUTICALS INC - PRIMARY ENDPOINT OF
EFFICACY, WAS
STATISTICALLY SIGNIFICANT VERSUS PLACEBO
    * VERRICA PHARMACEUTICALS INC - TORII INTENDS TO SUBMIT A
MANUFACTURING AND MARKETING APPLICATION FOR PRODUCT IN JAPAN

Source text for Eikon:  ID:nGNX4TPnfF 
Further company coverage:  VRCA.O 

 ((Reuters.Briefs@thomsonreuters.com;))